click below
click below
Normal Size Small Size show me how
ONC EXAM 2 TREATMENT
| DISEASE | TREATMENT |
|---|---|
| HIGH EMIETIC RISK - 3-4 meds | dexamethasone, 5HT (Palonosetron), and NK 1 (aprepitant) and olanzapine |
| MODERATE RISK - 2-3 meds | dexamethasone, 5HT, (Palonosetron) and maybe NK 1 (aprepitant) or olanzapine |
| LOW RISK - 1 med | dexamethasone or 5HT (serotonin receptor antagonist) (Palonosetron) or dopamine receptor antagonist |
| MINIMAL RISK - no meds | No prophylaxis |
| Anticipatory N/V | Lorazepam 1mg PO night before treatment and 1-2 hours before chemo Olanzapine 2.5mg PO night before chemo |
| Radiation emetic risk high-total body moderate-upper abdomen low-lower stomahch/pelvis/cranium/craniospinal minimal-head/neck/extremeties/breast | high-5HT +/- dexamethasone before and 24 hours after moderate-5HT +/- dexamethasone before low-5HT before minimal-5HT PRN |
| CID 1-2 | OTC dose loperamide, if no response escalate loperamide dose or give atropine/diphenoxylate if still no response give octreotide |
| loperamide 2mg | OTC dose: 2 caps at onset then 1 for every loose stool (8mg daily max) Escalated dose; 2 caps at onset then 1 cap every 2-4 hours for 12 hours (24mg daily max) must be 12 hours period of no diarrhea while on loperamide to d/c loperamide |
| CID 3-4 | no chemo, hospital admit, fluids/electrolytes, stool workup, potentially antibiotics octreoide 100-150 mcg subQ TID (100mcg IV contiuous/10-30mg IM Q28D) |
| Other diarrhea treatments | absporbents: attapulgite, polycarbophil If c. diff ruled out: OTC loperamide, pepto in people over 12 y/o/ budesonide/tincture of opium |
| Irinotecan induced early: cholinergic (from AcHe inhibition), in first 24 hours late: SN-38 metabolite, after 24 hours | early: atropine late: loperamide |
| abemaciclib induced diarrhea | starts within first 6-8 days loperamide 16mg daily total 4mg at onset 2mgq-2-4hr 12hrs Rx: diphenoxylate/atropine, opium tincture |
| Checkpoint inhibitor colitis | steroids, no response then IV steroids, no response then infliximab or vedolizumab |